Review
Antibody engineering for the development of therapeutic antibodies
Affiliations
- PMID: 16258237
Item in Clipboard
Review
Antibody engineering for the development of therapeutic antibodies
Mol Cells.
.
Free article
Abstract
Therapeutic antibodies represent one of the fastest growing areas of the pharmaceutical industry. There are currently 19 monoclonal antibodies in the market that have been approved by the FDA and over 150 in clinical developments. Driven by innovation and technological developments, therapeutic antibodies are the second largest biopharmaceutical product category after vaccines. Antibodies have been engineered by a variety of methods to suit a particular therapeutic use. This review describes the structural and functional characteristics of antibody and the antibody engineering for the generation and optimization of therapeutic antibodies.
Similar articles
-
Tailor-made antibody therapeutics.Methods. 2005 May;36(1):11-24. doi: 10.1016/j.ymeth.2005.01.002. Methods. 2005. PMID: 15848071 Review.
-
Generation of antibody molecules through antibody engineering.Methods Mol Biol. 2003;207:3-25. doi: 10.1385/1-59259-334-8:03. Methods Mol Biol. 2003. PMID: 12412465 Review. No abstract available.
-
Humanization and Simultaneous Optimization of Monoclonal Antibody.Methods Mol Biol. 2019;1904:213-230. doi: 10.1007/978-1-4939-8958-4_9. Methods Mol Biol. 2019. PMID: 30539472
-
Antibody therapeutics, antibody engineering, and the merits of protein stability.Curr Opin Drug Discov Devel. 2008 Sep;11(5):675-87. Curr Opin Drug Discov Devel. 2008. PMID: 18729019 Review.
-
Guided selection of a pan carcinoma specific antibody reveals similar binding characteristics yet structural divergence between the original murine antibody and its human equivalent.J Mol Biol. 2000 Feb 25;296(3):833-49. doi: 10.1006/jmbi.2000.3512. J Mol Biol. 2000. PMID: 10677285
Cited by
-
Turning Cancer Immunotherapy to the Emerging Immune Checkpoint TIGIT: Will This Break Through the Limitations of the Legacy Approach?Vaccines (Basel). 2024 Nov 22;12(12):1306. doi: 10.3390/vaccines12121306. Vaccines (Basel). 2024. PMID: 39771968 Free PMC article.
-
A specific photoimmunotheranostics agent to detect and eliminate skin cancer cells expressing EGFR.J Cancer Res Clin Oncol. 2016 May;142(5):1003-11. doi: 10.1007/s00432-016-2122-7. Epub 2016 Feb 3. J Cancer Res Clin Oncol. 2016. PMID: 26847542 Free PMC article.
-
Research and development of therapeutic mAbs: An analysis based on pipeline projects.Hum Vaccin Immunother. 2015;11(12):2769-76. doi: 10.1080/21645515.2015.1074362. Hum Vaccin Immunother. 2015. PMID: 26211701 Free PMC article.
-
Human TNF cytokine neutralization with a vNAR from Heterodontus francisci shark: a potential therapeutic use.MAbs. 2013 Jan-Feb;5(1):80-5. doi: 10.4161/mabs.22593. Epub 2012 Dec 5. MAbs. 2013. PMID: 23221782 Free PMC article.
-
Factors Affecting the Pharmacology of Antibody-Drug Conjugates.Antibodies (Basel). 2018 Feb 7;7(1):10. doi: 10.3390/antib7010010. Antibodies (Basel). 2018. PMID: 31544862 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
